Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report

Chiang Mai Medical Journal (Formerly Chiang Mai Medical Bulletin) is an official journal of the Faculty of Medicine, Chiang Mai University. It accepts original papers on clinical and experimental research that are pertinent in the biomedical sciences. The Journal is published 4 issues/year (i.e., Ma...

Full description

Saved in:
Bibliographic Details
Main Author: Chaichana Chantharakhit
Language:English
Published: Faculty of Medicine, Chiang Mai University 2019
Subjects:
gefitinib
hepatotoxicity
dose modification
Online Access:https://www.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/184817/130063
http://cmuir.cmu.ac.th/jspui/handle/6653943832/66337
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
id th-cmuir.6653943832-66337
record_format dspace
spelling th-cmuir.6653943832-663372019-08-21T09:18:26Z Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report ประสิทธิภาพของการปรับลดขนาดยา gefitinib ภายหลังเกิดผลขางเคียงต่อตับในผู้ป่วยมะเร็งปอดชนิดไม่ใช่เซลล์ขนาดเล็กในระยะลุกลามที่ผ่านการรักษามาหลายขนาน : รายงานผู้ป่วย Chaichana Chantharakhit gefitinib hepatotoxicity dose modification Chiang Mai Medical Journal (Formerly Chiang Mai Medical Bulletin) is an official journal of the Faculty of Medicine, Chiang Mai University. It accepts original papers on clinical and experimental research that are pertinent in the biomedical sciences. The Journal is published 4 issues/year (i.e., Mar, Jun, Sep, and Dec). Targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is a standard treatment for advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer. There is information evidence demonstrating the efficacy of progression-free survival in either both first line treatment or and second-line treatment. However, there is only limited information on the efficacy of treatment and dose modification on the occurrence of medication side effects, especially in late-line treatment patients, and most is limited to case reports rather than clinical studies. In this study we describe the use of gefi tinib in late-line treatment where the gefi tinib dosage was adjusted reduced to 250 mg every 2 days aft er patients had developed hepatitis due to gefitinib. There was a 21 week progression free interval which included a 13 week progression-free interval of following dose modification. 2019-08-21T09:18:26Z 2019-08-21T09:18:26Z 2019 Chiang Mai Medical Journal 58, 2 (Apr-June 2019), 99-104 0125-5983 https://www.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/184817/130063 http://cmuir.cmu.ac.th/jspui/handle/6653943832/66337 Eng Faculty of Medicine, Chiang Mai University
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
topic gefitinib
hepatotoxicity
dose modification
spellingShingle gefitinib
hepatotoxicity
dose modification
Chaichana Chantharakhit
Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
description Chiang Mai Medical Journal (Formerly Chiang Mai Medical Bulletin) is an official journal of the Faculty of Medicine, Chiang Mai University. It accepts original papers on clinical and experimental research that are pertinent in the biomedical sciences. The Journal is published 4 issues/year (i.e., Mar, Jun, Sep, and Dec).
author Chaichana Chantharakhit
author_facet Chaichana Chantharakhit
author_sort Chaichana Chantharakhit
title Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
title_short Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
title_full Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
title_fullStr Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
title_full_unstemmed Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
title_sort efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of egfr mutated advanced non-small cell lung cancer: a case report
publisher Faculty of Medicine, Chiang Mai University
publishDate 2019
url https://www.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/184817/130063
http://cmuir.cmu.ac.th/jspui/handle/6653943832/66337
_version_ 1681426435865051136

Similar Items